A company focused on discovering membrane-permeable and orally available cyclic-peptides, taking a mission-driven approach.

INSAMO

Insamo

Please join Insamo CEO Tim Craven in a conversation about "Undruggable Targets and the Advent of Generative AI" at SynBioBeta 2024, happening on May 7th from 2:45 to 3:30 pm. We're diving deep into how generative AI is revolutionizing the hunt for new small molecule targets, especially those in previously inaccessible areas of biology. This session promises to be a fascinating exploration of the interface between advanced computing and biotechnology, showcasing how AI-driven approaches are opening doors to new therapeutic possibilities. We'll discuss the challenges, breakthroughs, and ethical considerations of using AI to navigate the complex landscape of 'undruggable' targets, highlighting the potential for significant medical advancements.

#SynBioBeta2024

#Artificialintelligence is bridging the gap between #syntheticbiology and #medicine - Meet the innovative #companies leading the way: GRO Biosciences, Absci, Generate:Biomedicines, Insamo, Arvinas, Atomwise, Exscientia, Collaborative Drug Discovery - CDD Vault, CellVoyant, Asimov, Alltrna, BioLoomics, Inc., BigHat Biosciences, LabGenius, Profluent Bio, Arzeda, Dreamfold, VantAI, Hexagon Bio, bitBiome, Inc., Enveda Biosciences: https://lnkd.in/gTjz9aEd #SynBioBeta2024 #synbio #AI Thank you to Jenna Gallegos

INSA

COM:INSAMO

INSAMO